Loading...

Innovative Health Solutions.
  • Antibiotic
    resistance
    is now a major threat to public health - WHO
  • Westway Health
    are developing
    non-antibiotic treatments to treat bacterial infections
  • Bacteria unable
    to gain resistance
    to Westway non-antibiotic technology
  • Platform
    technologies
    with applications in Human Health, Animal Health and
    Environmental Applications
  • Lead Product
    in Development
    PanaMast™ LC – the world’s first zero
    withdrawal mastitis treatment
A new model for a post-antibiotic era

Westway Health are leading the development of novel anti-infective agents, those which can address the current rise of antibiotic-resistant bacteria, while providing effective therapeutic care.

The Opportunity

Experts are describing the growing emergence of antibiotic-resistant bacteria as a ‘ticking time bomb’, which could return healthcare to a pre-antibiotic era, where common infections can become fatal. Anti-infective agents which can eradicate such microorganisms without a conferring a resistance are required.

The Solution

Westway Health have developed and are commercialising a range of novel non-antibiotic antimicrobial technologies. While differing in their composition, mechanism of action, they share a number of common attributes, including the ability to eradicate all microorganisms (including resistant microorganisms) while preventing a resistance to be gained to the technologies

The Objective

Westway Health aims to bring our innovative solutions to the clinic and market, providing a safe and effective means of treating infection. We have active development programmes for a number of human and animal diseases, with our lead product for the treatment of bovine mastitis. This we believe can offer a glimpse into a safe, effective post-antibiotic era.

Welcome to Westway Health

We were established in Galway, Ireland in 2012 to develop and commercialise our innovative, natural antimicrobial LARS – Long Acting Reactive Species- technology, originally developed in the laboratory of Prof. Vincent O’Flaherty in the National University of Ireland, Galway. We have a strong management team, experienced in the veterinary field, and an exciting pipeline of groundbreaking new products - underpinned by excellent research and development.

"Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill." - Dr Keji Fukuda, assistant director-general, WHO